v3.26.1
Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Income Tax Disclosure [Abstract]    
Royalty agreement liabilities $ 5,415 $ 3,913
Net operating loss 91,962 81,971
Section 174 R&D capitalization 5,797 6,288
Stock-based compensation 1,791 419
Accrued expenses and other 690 744
Other tax credits 589 24
Orphan drug credit 199 199
Lease liabilities 158 0
Startup costs 76 86
Deferred tax assets before valuation allowance 106,677 93,644
Right of use assets (142) 0
Other deferred tax liabilities (400) (390)
Net deferred tax 106,135 93,254
Valuation allowance (106,135) (93,254)
Net deferred tax assets 0 0
(Increase) decrease in valuation allowance $ (12,881) $ (77,240)